Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > New Patent + Advancing New DPEP-1 Drugs = Phase II Results

<< Previous

Bullboard Posts

Next >>

Comment by Riverfolkon Oct 02, 2021 9:06am

103 Views

Post# 33957238

RE:RE:New Patent + Advancing New DPEP-1 Drugs = Phase II Results

Does Arch have other drugs targeting DPEP-1?

"Yes, we have been working on this pathway for several years and while Lsalt is the leading candidate we have developed a number of other molecules that target the DPEP-1 pathway. This includes a variety of novel Peptides, Peptides that have been modified to improve there pharmacologic properties, were also developing antibodies that target DPEP-1. We will be advancing two of our molicules into the preclinical pipeline in the next month or two"

Dr. Daniel Muruve

Webinar - 36:00

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec